- Recursion Pharmaceuticals partners with Enamine to enhance AI-driven drug discovery.
- Average analyst target hints at an 88.47% upside potential for RXRX.
- GuruFocus projects a 209.76% upside based on the GF Value estimate.
Recursion Pharmaceuticals Inc. (RXRX, Financial) has embarked on a transformative collaboration with Enamine to refine their drug discovery processes. By leveraging its cutting-edge AI/ML platform, Recursion OS, alongside Enamine's extensive chemical library, this partnership targets to expedite the identification and development of 100 key drug targets, thus revolutionizing the pharmaceutical landscape.
Wall Street Analysts Forecast
According to insights from 6 Wall Street analysts, Recursion Pharmaceuticals Inc. (RXRX, Financial) holds an average one-year price target of $8.50. This forecast includes a high projection of $11.00 and a low projection of $6.00, indicating a potential upside of 88.47% from its current trading value of $4.51. For a more in-depth analysis, visit the Recursion Pharmaceuticals Inc (RXRX) Forecast page.
The consensus from 8 brokerage firms rates RXRX with an average recommendation of 2.8, signaling a "Hold" position. The rating scale spans from 1 (Strong Buy) to 5 (Sell), reflecting the mixed sentiment in the current market environment.
GuruFocus's proprietary GF Value puts Recursion Pharmaceuticals Inc. (RXRX, Financial) at an estimated valuation of $13.97 in a year's time. This suggests a remarkable potential upside of 209.76% from its present market price of $4.51. The GF Value is a calculated estimate reflecting the stock's fair trading value, derived from historical trading multiples, previous business growth, and future performance forecasts. Additional insights and data are available on the Recursion Pharmaceuticals Inc (RXRX) Summary page.
